Today: 21 May 2026
Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher
23 January 2026
1 min read

Atul Q3 results: profit jumps 40% but labour-code costs bite; shares end higher

Mumbai, Jan 23, 2026, 16:14 IST

Atul Ltd shares finished roughly 1% up on Friday following a strong quarterly profit report from the Indian speciality chemicals company. The stock closed at 5,833.25 rupees, marking a 1.03% gain.

As India’s December-quarter earnings season unfolds, investors are sorting out signal from noise. In chemicals, even a slight move in costs or pricing quickly impacts margins.

Labour costs have added a new wrinkle. Firms are now wrestling with how India’s new labour codes affect the accounting of certain employee benefit expenses.

Indian stocks closed lower, the Nifty 50 slipping 0.95% to 25,048.65.

Atul reported a consolidated net profit of 163.54 crore rupees for the October-December quarter, the third in its 2025-26 fiscal year ending March. Revenue for the period reached 1,573.62 crore, marking an 11% rise from a year ago, while profit jumped nearly 40%. However, profit slipped compared to the previous quarter despite a slight increase in sales. Revenue from life science chemicals fell marginally, whereas performance and other chemicals saw growth. The company also noted a 36.61 crore rupee provision in its standalone accounts related to the new labour codes.

Costs kept climbing. Operating expenses increased 2.9% from the previous quarter, reaching 1,410.06 crore rupees. Employee benefit expenses surged to 166.73 crore, which included a 41.35 crore rupee provision tied to labour code changes. For the nine months ending Dec. 31, revenue grew 11.4% to 4,603.47 crore, while profit rose to 478.27 crore, the report noted.

Atul reported EBITDA of roughly 248 crore rupees, with its margin slipping slightly to 15.7% from 15.8% the previous year, ET Now said.

Sunil Lalbhai serves as the chairman of the company. Its publicly traded competitors in India’s speciality chemicals sector include Navin Fluorine International, Deepak Nitrite, and Vinati Organics, based on market data services.

The key variable remains whether labour-code related provisioning and employee expenses stay high — and if demand remains strong enough for producers to maintain price hikes. Should costs remain elevated while pricing falters, earnings could drop sharply, even if sales stay steady.

Stock Market Today

  • Asian Shares Rise on Oil Price Drop and Nvidia's Strong AI-Driven Earnings
    May 21, 2026, 1:31 AM EDT. Asian shares surged Thursday, led by South Korea's Kospi gaining 8%, following Wall Street's AI-driven rally and easing bond market pressure. Nvidia's quarterly profit jumped over 200%, fueled by demand for its AI chips, boosting tech stocks like Samsung Electronics, which rose 7.5%, and SK Hynix, up 11.3%. Taiwan's Taiex added 3.9%, supported by TSMC's 3% increase. Japan's Nikkei climbed 3.6% aided by a 15% rise in exports. Oil prices fell sharply, with Brent down 5%, arousing hopes of renewed U.S.-Iran oil supply talks, before a partial rebound. U.S. stocks also recovered, with the S&P 500 up 1.1% as 10-year Treasury yields eased, reducing pressure on equities amid inflation and interest rate concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Previous Story

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
Next Story

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

Go toTop